A Phase III Trial of AZD0780 on Major Adverse CV Events
Phase 3
15,100
about 4.4 years
18+
293 sites in AL, AZ, CA +38
About this study
Researchers are testing whether AZD0780, a medication, reduces the risk of major adverse cardiovascular events (MACE) in people who have already had heart problems or are at high risk for developing them. The trial will last 1605 days and involve approximately 15100 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AZD0780
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Time to first event of any component of MACE-PLUS
Secondary: Time to first event of any component of 3P MACE, Time to first event of any component of MACE PLUS
Cardiology / Heart